SyntaxBio
- Company typePrivate
- Founded2024
- HeadquartersChicago, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
SyntaxBio firmographics
Firmographics- Name
- SyntaxBio
- Legal name
- Syntax Bio
- Website
- https://syntax-bio.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
SyntaxBio industry classification
Industry- Product category
- Cell Therapy Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
- akta.pro secondary industries
- CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
Keywords
Where SyntaxBio is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
SyntaxBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Biopharma Discovery Partnerships: Upfront R&D payments, milestone-based fees, and royalties from biopharmaceutical companies. Capital-efficient model that captures significant downstream economics from therapeutic development programs.
- Platform Collaboration Fees: Partnerships structured with upfront payments for platform access and evaluation, with additional payments tied to development milestones.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
SyntaxBio product offering
Product offeringCore offering
Syntax Bio develops a proprietary CRISPR-based Cellgorithm™ discovery platform that programs step-wise cellular differentiation processes by providing customizable, epigenetic instructions that mimic human embryonic development. The platform enables rapid generation of a wide diversity of functional cell types from human stem cells with reduced growth factor requirements, and is delivered through biopharma discovery partnerships including upfront R&D payments, milestone fees, and royalties. The company's lead therapeutic program uses this platform to produce insulin-producing pancreatic beta cells for Type 1 Diabetes.
Product overview
SyntaxBio operates as a preclinical-stage synthetic biology company offering the Cellgalgorithm Platform as its core technology, complemented by the proGuide programmable gene activation system. The platform provides customizable, epigenetic instructions to program step-wise cellular differentiation processes, enabling faster production of various cell types from human stem cells. The company's primary therapeutic focus is the Pancreatic Beta Cell Therapy Program for Type 1 Diabetes. Business model includes biopharma discovery partnerships structured with upfront R&D payments, milestone-based fees, and royalties. Collaborations with Ajinomoto evaluate StemFit culture media products for platform compatibility.
Differentiator
Problem solved
Functional benefit
Brands
- Cellgalgorithm: Proprietary CRISPR-based platform technology for controlling gene activity in human stem cells to program step-wise cellular differentiation processes
- proGuide
Products and services
- Cellgorithm™ Platform CRISPR-based discovery platform providing customizable, epigenetic instructions to program step-wise cellular differentiation processes, mimicking human development to generate functional cell types with reduced growth factor requirements. Sold to large biopharmaceutical organizations and academic medical centers through discovery partnerships.
- proGuide System Programmable gene activation system using CRISPR-based technology to control gene expression with temporal precision, enabling ordered activation of genes to address challenges in cellular developmental programming.
- Pancreatic Beta Cell Therapy Program
Quantifiable outcome
- Differentiation timeline reduced from 4 months to less than 2 weeks
- +1 more outcomes
Companies that use SyntaxBio
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
SyntaxBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
SyntaxBio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Applied StemCellcoreStrategic collaboration announced June 23, 2026 to advance stem cell innovation. Details focused on combining Applied StemCell's expertise with Syntax Bio's Cellgalgorithm platform.
- Ajinomoto Health & Nutrition North America, Inc.coreCollaboration to evaluate Ajinomoto Group's StemFit™ stem cell culture products using Syntax Bio's Cellgorithm™ platform. AHN provides StemFit™ culture media products to demonstrate platform compatibility and workflow optimization for next-generation cell therapies.
- Mayo CliniccoreR&D collaboration to advance stem cell-derived pancreatic beta cell therapies for type 1 diabetes. Mayo Clinic also participated as an investor in the expanded Series A round. Collaboration aims to advance therapeutic development through preclinical proof of concept.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
SyntaxBio competitors and assessment
Company assessmentDirect peers
- bit.bio: bit.bio operates a cell programming platform (opti-ox) that genetically engineers iPSCs into specific cell types — the closest direct competitor to Syntax Bio's Cellgorithm, serving similar biopharma discovery customers with comparable differentiation technology.
- BlueRock Therapeutics: BlueRock Therapeutics (a Bayer-owned subsidiary) develops engineered cell therapies using iPSC-derived pluripotent cells, with a similar focus on differentiation protocols for regenerative medicine applications including cell therapy for diseases like Parkinson's.
- Notch Therapeutics: Notch Therapeutics develops iPSC-derived immune cell therapies using proprietary Engineered Thymic Niche technology for T-cell manufacturing, operating as a direct peer in the programmable cell therapy manufacturing space.
- Century Therapeutics: Century Therapeutics develops engineered iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases, positioning it as a direct peer in the iPSC-based cell therapy development space that Syntax Bio's platform enables.
- Fate Therapeutics: Fate Therapeutics is a clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell products, directly competing for the same regenerative medicine / cell therapy customer base that Syntax Bio serves with its differentiation platform.
- Aspect Biosystems: Aspect Biosystems develops bioprinted tissue therapeutics using proprietary cell differentiation and 3D bioprinting technology, representing a direct peer in cell differentiation platforms for therapeutic development.
Broad incumbents
- Sana Biotechnology: Sana Biotechnology develops engineered cells as medicines, including iPSC-derived allogeneic cell therapies, positioning it as a broad incumbent with overlapping programmable cell therapy capabilities targeting similar indications.
- Ginkgo Bioworks: Ginkgo Bioworks operates a broad synthetic biology platform that includes cell engineering services, positioned as a broad incumbent that offers programmable biology capabilities overlapping with Syntax Bio's CRISPR-based differentiation approach.
Emerging players
- Cellino Biotech: Cellino Biotech combines AI, laser editing, and stem cell biology for autologous cell therapy manufacturing, representing an emerging peer addressing scalability and reproducibility in cell therapy manufacturing.
- TreeFrog Therapeutics: TreeFrog Therapeutics offers a cell therapy manufacturing platform (C-Stem) that encapsulates and differentiates stem cells at scale, representing an emerging peer focused on solving manufacturing scalability — a key customer pain point Syntax Bio addresses.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SyntaxBio social profiles
Digital presenceSyntaxBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
SyntaxBio leadership team
Management profileNumber of profiles
Profiles4 records
SyntaxBio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SyntaxBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SyntaxBio
What does SyntaxBio do?
Syntax Bio develops a proprietary CRISPR-based Cellgorithm™ discovery platform that programs step-wise cellular differentiation processes by providing customizable, epigenetic instructions that mimic human embryonic development. The platform enables rapid generation of a wide diversity of functional cell types from human stem cells with reduced growth factor requirements, and is delivered through biopharma discovery partnerships including upfront R&D payments, milestone fees, and royalties. The company's lead therapeutic program uses this platform to produce insulin-producing pancreatic beta cells for Type 1 Diabetes.
Is SyntaxBio a public or private company?
SyntaxBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was SyntaxBio founded?
SyntaxBio was founded in 2024. It employs 11 to 50 people.
Where is SyntaxBio based?
SyntaxBio is headquartered in Chicago, United States, in the North America region.
How does SyntaxBio make money?
Two revenue lines are on record. Biopharma Discovery Partnerships are the primary driver. The others are platform Collaboration Fees.
Who are SyntaxBio's main competitors?
Direct peers on record are bit.bio, BlueRock Therapeutics, Notch Therapeutics, Century Therapeutics, Fate Therapeutics and Aspect Biosystems. Broad incumbents are Sana Biotechnology and Ginkgo Bioworks. Emerging players are Cellino Biotech and TreeFrog Therapeutics.
Does SyntaxBio have an API?
No public API is recorded for SyntaxBio.
What industry is SyntaxBio in?
SyntaxBio's product category is Cell Therapy Discovery Platform. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq). Its NAICS code is 541714 and its SIC code is 2836.